Author:
Cardoso Fatima,Cella David,Velikova Galina,Harmer Victoria,Schumacher-Wulf Eva,Rihani Julie,Casas Ana,Harbeck Nadia
Funder
Breast Cancer Now
Merck
Astex Pharmaceuticals
Novartis International AG
Novartis Institutes for BioMedical Research
Pfizer
Novartis Pharmaceuticals Corporation
Subject
Radiology, Nuclear Medicine and imaging,Oncology,General Medicine
Reference77 articles.
1. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. V.6.2020.
2. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline;Partridge;J Clin Oncol,2014
3. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5);Cardoso;Ann Oncol,2020
4. EMA. Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003637.pdf; 2005 [accessed 29 July 2021].
5. FDA. Guidance for industry clinical trial endpoints for the approval of cancer drugs and biologics. https://www.fda.gov/media/71195/download; 2018 [accessed 29 July 2021].
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献